SCHEDULE 13G/A: BlackRock Amends Stake in Kiniksa Pharmaceuticals, Reports 5.4% Beneficial Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.4% beneficial ownership stake in Kiniksa Pharmaceuticals International, plc as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,262,066 shares of Kiniksa Pharmaceuticals International, plc common stock.
- This represents 5.4% of the total outstanding common shares of Kiniksa Pharmaceuticals International, plc.
- BlackRock, Inc. holds sole voting power over 2,221,773 shares and sole dispositive power over 2,262,066 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- The filing is an Amendment No. 3 to the Schedule 13G.
- Kiniksa Pharmaceuticals International, plc's principal executive offices are located at 23 OLD BOND STREET, FLOOR 3 LONDON, United Kingdom WIS 4PZ.
- BlackRock, Inc.'s principal business office is at 50 Hudson Yards, New York, NY 10001.
Sentiment
Score: 5
Explanation: The document is a factual, regulatory filing disclosing beneficial ownership. It contains no positive or negative sentiment regarding the issuer's performance or outlook, maintaining a neutral tone.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Kiniksa Pharmaceuticals International, plc's future performance or BlackRock's investment strategy beyond the current ownership disclosure.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., indicating its passive ownership stake in a pharmaceutical company. Such filings are common and reflect portfolio management activities rather than specific industry trends, though they provide transparency into significant institutional holdings within the healthcare sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a passive investment approach by BlackRock, Inc.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney granted by BlackRock, Inc. |
| 2025-03-31 | Date of event which required the filing of this Schedule 13G amendment. |
| 2025-04-23 | Date the Schedule 13G Amendment No. 3 was signed by BlackRock, Inc. |
Keywords
BlackRock, Kiniksa Pharmaceuticals, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.